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                                                                                     ABSTRACT 
TITLE: “ROLE OF HYPERFRACTIONATED RADIOTHERAPY WITH WEEKLY 
DOCETAXEL IN LOCALLY ADVANCED UNRESECTABLE HEAD AND NECK CANCER” 
DR.S.JEYASANKAR, PROF DR.S.SHANMUGAKUMAR MDRT,PROF DR.N.V.KALAIYARASI 
MDRT  
Aims And Objectives: 
                   To assess the immediate loco regional response rates of locally advanced unresectable 
squamous cell carcinomas of the head and neck cancer   treated with hyperfractionated radiotherapy and 
concurrent weekly Docetaxel.   
                   To assess the acute toxicities of the treatment.  
Materials And Methods: 
                    Eligible 30 patients were taken up for concurrent chemotheraphy with hyperfractionated 
radiotherapy 120 centigray twice daily fractions with a gap of 6 hours, 5 days in a week along with 
inj.docetoxel 20 mg/m2 weekly. Patients were  assessed clinically during treatment for toxicity and 
response 6 weeks after completion of treatment  .  
Results: 
 Female sex showed higher complete responses than male. Stage-III cancers shows higher 
complete responses than stage IV A. Moderately and poorly differentiated cancers showed a considerable  
complete response. Lower the T stage higher is the complete response. Lower the N stage higher is the 
complete response and lower the TNM stage group higher is the complete response. Hypopharyngeal and 
oropharyngeal tumors produced greater complete response. Complete response rate in primary T3 and 
T4A tumors are 90% and 70% respectively. Complete response rates attained by N0, N1, N2A, and N2C 
nodes are 100%, 90%, 50% and 63% respectively. Primary and secondary complete response was 
achieved by 76% high complete responses were achieved by T3N0 (100%), T3 N1 (100%), then by 
T3N2A(50%),T3 N2C (66.66%),T4A N1 (70%) and last by T4A N2C (60%). 63.33% had grade 3 
mucositis.  73.33% had grade 2 and 3.33% had grade 3 skin toxicities. 10% had grade 3 laryngitis. No 
grade 3, 4 hematological toxicities  and in anemia. No Grade 3, 4 hematological toxicities in leucopenia 
or thrombocytopenia were observed.  There was no grade III or IV vomiting. 
                  Conclussion 
                  Docetaxel is one of the effective agent in head and neck cancers with manageable toxicities. 
This study shows that concurrent chemo radiotherapy using hyperfractionated radiotherapy combined 
with low dose weekly docetaxel produces complete response rate 76%. 
 Keywords. Hyperfractionated RT, concurrent chemotherapy, docetaxel, head and neck cancer 
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INTRODUCTION 
GLOBAL BURDEN OF HEAD AND NECK CANCER 
The number of newly diagnosed cancers worldwide in 2008 
was approximately 12.7 million, with 5.6 million cases from the 
economically more developed countries and 7.1 million from the 
less developed countries 
[9]
. Worldwide 560,000 cases of head and 
neck cancer are diagnosed every year, and 300,000 patients died 
because of it. 
[10].
  
In 2009, 48010 new head and neck cancer cases have been 
detected in United States and this represents 3.2% of the total new 
cancer load 
[6]
. Two thirds of the new cancer cases diagnosed in the 
world are from developing countries like India. Southeast Asia will 
face sudden increase in number of cancer deaths more than 50%.  
High rate of occurrence of oral cavity cancers is reported from 
Australia, India, South Africa and Western Europe. 
[11]
 Cancer 
incidence rate is maximum in India among the SAARC countries 
[3]
. 
INDIAN BURDEN OF HEAD AND NECK CANCER 
Head and neck cancers are the 2nd most common cancers in 
men and fourth most common cancer in women in India 
[3]
. Head 
and neck cancers are the most common cause of death in the 25 to 
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60 years age group following cardiovascular disease, respiratory 
disease and tuberculosis 
[3]
.  
At present the total population of India is 1.2 billion. At any 
given point of time there are 240 thousand cancer patients 
according to WHO report 
[3,28]
. Head and neck cancers contribute to 
the total incidence of cancer around 33% in India whereas it is only 
10% in western countries 
[5] .
The estimates of head and neck cancer 
in men for the year 2015,it is 1lakh 53 thousand in men and 64 
thousand in women 
[7]
. 
 TAMILNADU  
Most common cancer in men is head and neck cancer 
(19.23%) followed by stomach cancer (13.98%) and then by lung 
cancer (12.46%).In women, breast cancer is the most common 
(20.87%) followed by cervical cancer (11.46%) then by stomach 
cancer (8.11% ) and head and neck cancer (7.53%). Tobacco use is 
the major cause for head and neck cancer in tamilnadu
[8]
. The 
incidence of oral cavity cancers shows a rising trend. 
Head and neck is the most essential structure for 
physiological functions like respiration, nourishment, verbal 
communication and appearance, which are only one of its kind.  
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Any kind of surgical procedure, reconstruction, radiation and 
chemotherapy induced toxicities has got a lot of difficulties over 
the normal physiological functions; causes disfigurement and 
decreases the quality of life. 
ETIOLOGY 
It is estimated that most of cancer deaths are due to tobacco, 
alcohol consumption, harmful dietary habits, and infection 
[4].Among the causes, tobacco use in any form is the world’s most 
preventable cause for head and neck cancer. There are one billion 
smokers and millions of smokeless tobacco users in the world 
[1, 2]
. 
EPIDEMIOLOGY OF TOBACCO  
In India, 274.9 million tobacco users there; 163.7 million 
people using smokeless form of tobacco; 68.9 million adults use 
smoking form of tobacco only and 42.3 million people utilize both 
smoking and smokeless forms of tobacco.14.1% of children age 
between 13 and 15 years use tobacco. In general tobacco usage 
among men is around 48% and in women it is 20%.  
SMOKING TOBACCO 
Cigarettes are the most common form of tobacco worldwide. 
Various form of smoking tobacco are cigar, beedis and cigarettes.  
Beedis which are consisting of tobacco flakes wrapped in temburni 
 4 
leaf with a little thread at one end are very popular in India. The 
puff` rate of beedi is higher than that of an unfiltered cigarette 
which is the reason for the increased carcinogenic load of beedis. 
Nicotine is the major central nervous system stimulant 
present in tobacco. It increases the available dopamine in nucleus 
and causes mood elevation  and  causing addiction. Major 
carcinogens in tobacco causing cancer are polycyclic aromatic 
hydrocarbons, NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanol] and NNN (N1-nitroso nor nicotine). 
SMOKELESS TOBACCO 
Worldwide there is increase in use of other nicotine 
deliverance like snuff, lozenges,betel quid. Betel quid is widely 
used in India. It is also called as pan which contains   pieces of 
areca nut, tobacco and slaked lime. Additional to this are spice, 
cardamom, cloves, according to their need. Pan also called as 
gutkha, zarda, mawa, khaini. 
Irritable substance in the Areca nut is notorious to cause  oral 
submucous fibrosis. Smokeless tobacco is not an equal form to 
compare smoking tobacco. Definitely the content of nicotine and 
the carcinogens are many times increased in smokeless tobacco.  
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ALCOHOL 
Tobacco and alcohol combined that increases the risk of 
developing head and neck cancer many fold. Both of it acts 
synergistically. Alcohol is a predictor of survival 
[4].
 Prognosis for 
alcoholic head and neck cancer patients is not as good as when 
compare the non alcoholic patients. Because most of them have 
advanced disease at presentation, suppressive immune status, 
diseases attributed to alcohol consumption, harmful nutritional 
habits, and emotional disturbances. 
HUMAN PAPILLOMA VIRUS INFECTION: 
Most of the oropharyngeal cancers associated with HPV 
infection. Most common human papilloma virus inked is HPV 16. 
Main route of spread is through oral sex. 30-40% of oropharyngeal 
cancers, 24% of oral cavity carcinoma were associated with HPV. 
Other common subtypes are HPV 18 and 31.  
OTHER CAUSES 
Other causes are iron deficiency (Plummer Vinson 
Syndrome), vitamin A deficiency, sharp tooth and occupational 
exposure like asbestos, nickel, chromium, by product of leather 
work and wood working 
[17]
.  
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More than half of the patients presented with locally 
advanced disease in our department. Ninety five percent are 
squamous cell carcinoma. Rest of the five percent includes 
verrucous carcinoma, minor salivary gland tumors, melanomas, 
adeno carcinoma, lympho epitheliomas, and lymphoma. 
Oral cavity ulceration, bleeding from the mouth ,sore throat, 
dysphagia, hoarseness of voice, earache, pain, numbness of the 
face, dyspnoea, difficulty in speech  or inability to open the mouth 
and headache  are the common symptoms during presentation.  
The work up include a thorough history and physical 
examination. Then clinical examination of the  primary with  fiber 
optic endoscope, biopsy, chest imaging, CT or MRI imaging of the 
tumor and neck, blood investigations and dental care. 
OVERVIEW OF TREATMENT OF SQUAMOUS CELL 
CARCINOMA OF HEAD AND NECK 
Multimodality treatment approach for head and neck cancers 
at present practiced are 
1) Surgical excision followed by adjuvant radiotherapy with or  
without  chemotherapy 
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2) Definitive chemo radiotherapy followed by surgery as 
salvage. 
3) Induction chemotherapy followed by definitive loco regional 
therapy. 
SURGERY 
Surgery is a part of the multimodality treatment approach. It 
has evolved in the recent years owing to outstanding reconstruction 
procedures. Robotic microsurgical techniques, imaging modalities 
and surgical pathology also advances. Surgical resection is 
classified as-resectable, unresectable and inoperable. 
RESECTABLE 
Surgical feasibility of a head and neck cancer is assessed by a 
multidisciplinary team. The excision of advanced cancers of oral 
cavity, pharynx and  larynx is by an en bloc resection to gain 
adequate resected margins.  
An adequate margin when the clearance is about 1.5 cm to 
2cm in frozen section. A clear margin is as a distance of ≥ 5 mm 
from the resected margin to the invasive tumor. A close margin is a 
distance of < 5 mm. Resection is usually through a transoral, 
transcervical approach or, through mandibular excision.     
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Reconstruction of surgical area by primary closure, skin graft, 
regional flap or a free tissue transfer. Reconstructed area should 
functionally and anatomically look like the normal tissue.  
NECK DISSECTION  
Elective neck dissection should be performed in clinically 
negative nodal disease in neck. Curative neck dissection should be  
done in patients with clinical evident of node positive disease. 
Based on the clinical, imaging and preoperative finding, therapeutic 
dissections is either selective neck dissection or a comprehensive 
neck dissection. Tumors crossing midline or primary with bilateral 
lymphatic drainage should undergo bilateral neck dissection. 
UNRESECTABLE  
Carcinoma is considered unresectable by the surgeon if the 
tumors could not be excised to give an adequate margin. Not only 
margin, local and regional control even after postoperative chemo 
radiotherapy to the treatment. When surgical procedure produces   
unacceptable morbidity, then patients can go with definitive 
radiotherapy or chemo radiotherapy with the same outcome as that 
of surgery.  
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INOPERABLE 
Constitutional state of the patient precludes surgery. The 
tumor may be resectable with least morbidity.  
SALVAGE SURGERY 
Patients with advanced head and neck cancer treated with, 
definitive radiatherapy or chemo radiatherapy, may have residual 
disease or with recurrence in the primary site or nodal site. So they 
should be   monitored periodically. They should undergo salvage 
surgery if there is a residual or recurrent disease.  The complication 
rates after salvage surgery is more when compared with upfront 
surgery. 
RADIOTHERAPY 
Primary and macroscopic nodal disease are to be treated with 66 
to 74 Gy in conventional 2 Gy fractions. Low to intermediate risk of 
lymphadenopathy to be treated electively between 44 and 64 Gy. 
Advanced T stage, depth of invasion, perineural invasion, multiple 
positive nodes, lymphovascular invasion requires postoperative 
radiotherapy. Extra capsular extension and positive margins are 
indication for post operative chemoradiation. Postoperative 
radiotherapy is administered between 4 and 6 weeks after surgery. 
Radiotherapy may be conventional or altered fractionation. 
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ALTERED FRACTIONATION 
ACCELERATED RADIOTHERAPY 
The overall treatment time is reduced. So  tumor cells 
regeneration is less during the treatment. Hence better local and 
regional control is achieved. 
Pure accelerated radiotherapy: 
Here the overall treatment time is reduced but no change in 
the total dose or fraction size. 
Hybrid accelerated fractionation: There are three types.  
Type A: Drastic reduction in overall treatment time and also 
considerable reduction in the total dose. 
Type B: Treatment time is reduced, total dose remains the 
same with an additional break in between treatment.  
Type C: Total dose is same; overall treatment time is 
decreased with an addition of a concomitant boost phase 
(Accelerated concomitant boost). 
HYPER FRACTIONATED RADIOTHERAPY  
In hyper fractionated radiation therapy, total dose of radiation 
is increased, dose per fraction is significantly reduced, the numbers 
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of fractions are increased and overall treatment time is significantly 
unchanged. 
CHEMOTHERAPY 
Benefits of chemoradiation are independent cytotoxicity of 
each of the modality, spatial cooperation, enhancement of tumour 
response by radio sensitisation and tackling of the systemic micro 
metastasis. 
RADIOTHERAPY AND CHEMOTHERAPY INTERACTION 
MECHANISMS 
INCREASING INITIAL RADIATION DAMAGE:     
Chemotherapy increases the initial DNA damage by single 
stranded and double stranded DNA breaks, base damage ,DNA-
DNA and DNA protein cross links. 
INHIBITION OF CELL 
Both sub lethal and potentially lethal damage produced by 
radiation can be repaired. Chemotherapy drugs interfere with DNA 
repair mechanisms and increase response to radiotherapy.  
CELL CYCLE REDISTRIBUTION 
The G2M phase of cell cycle is three times more susceptible 
to radiation than S phase. Chemotherapy drugs like taxol block 
progression of cell cycle in the transition through mitosis phase and 
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all cells accumulate in the G2M phase. So when taxol is added to 
radiotherapy there is an enhanced tumour kill. 
OVERCOMING TUMOR HYPOXIA 
Radiotherapy and chemotherapy preferentially kill the 
actively proliferating cells in the oxic regions of the tumour. With 
each dose of radiosensitiser chemotherapeutic drug and radiation, 
the well oxygenated cells in the periphery of tumour die. There is a 
gross fall in the interstitial pressure within the tumour causing 
opening up of previously closed capillaries and redirection of blood 
to the hypoxic regions of the tumour. 
INHIBITION OF TUMOR CELL REPOPULATION 
Chemotherapy is both tumoricidal and tumoristatic. By using 
a combination there is a hastened killing of tumour cells and 
reduction in the rate of treatment related accelerated repopulation 
of cancer. 
The current study protocol takes the benefit of hyper 
fractionated radiotherapy and concurrent usage of chemotherapeutic 
sensitizers namely docetaxel . 
DOCETAXEL  
Classified as a Anti-microtubule agent 
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MECHANISM OF ACTION 
It is active in the Mitosis (M) phase of the cell cycle and has 
a high-affinity towards microtubules and enhances tubulin 
polymerization. The tubulin thus formed are resistant to 
disassembly by normal physiological process and they accumulate 
as disorganised array
 [13]
. Docetaxel is more effective at inducing 
apoptosis and inhibiting anchorage-independent cell growth .
[23] 
MECHANISM OF RESISTANCE 
Alterations in tubulin, increased expression of P 170 
glycoprotein resulting in enhanced drug efflux and decreased 
intracellular accumulation of drug causes resistance to the drug.  
The drug is poorly soluble and not orally bio available.  
It is widely distributed to all body tissues and excessively 
protein bound.  
Metabolised by hepatic P 450 enzyme. 70% to 80% are 
excreted by faecal route with a terminal half life ranging from 9 to 
50 hours. Cross resistance also  will occur with other products like 
Vinca alkaloids,Anthracyclines and Etoposide. 
Docetaxel is indicated in a broad range of cancers like ovary, 
breast, lung, head and neck, oesophagus, prostate, bladder and 
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AIDS-related Kaposi's sarcoma. Myelosuppresion is a dose limiting 
toxicity. Neutropenia is more common with a nadir at 8 days and 
recovery between day 15 and 21; hypersensitivity is prone to occur 
in 20% to 40% patients. Also peripheral neuropathy, mucositis, 
diarrhoea and alopecia may occur. 
SUMMARY OF MECHANISMS OF INTERACTION 
BETWEEN HYPER FRACTIONATED RADIOTHERAPY 
WITH DOCETAXEL  
REPAIR OF SUBLETHAL DAMAGE 
Hyperfractionated radiotherapy with an inter fraction interval 
of not less than 6 hours allows repair of sublethal damage repair in 
normal tissues. In twice daily fractionation, an absolute minimum 
interfraction interval of 6 hours was advocated by EORTC 22791 
and 22851. So dose escalation is possible without increasing the 
late toxicities. 
REDISTRIBUTION OF THE CELL CYCLE 
Docetaxel accumulates the cells in the G2M phase and 
increases the number of cells in the radiosensitive phase. So cell 
killing is enhanced in the next hyperfractionated dose.  
REPOPULATION 
Increased and effective killing of cells right from day 1 of 
radiation decreases both the tumor bulk and repopulation steadily. 
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REOXYGENATION 
Oxygen enhancement ratio is lower. 
THERAPEUTIC INDEX 
It is defined as the ratio of the tumor response to a fixed level 
of normal tissue damage. To be therapeutically beneficial, the ratio 
should be greater than 1. There is a precarious balance between the 
antitumor activity and the normal tumour tissue toxicity.  Many 
clinical parameters like a palliative or a curative choice of 
treatment, dose limiting structures, amount of toxicity acceptable, 
and the individual patient’s radio sensitivity influence the 
therapeutic ratio. 
EXPLOITABLE STRATEGIES IN CHEMORADIATION:                   
Radiation has attained a pinnacle of improvement in various 
avenues like technological advances, combination treatment with 
chemotherapy altered fractionation schedules, biological agents, 
targeted agents and hypoxic cell sensitizers. All these modalities 
have to be explored to generate optimum treatment schedules.  
RADIOBIOLOGICAL RATIONALE FOR 
HYPERFRACTIONATION 
Smaller dose fraction allows a higher total dose to be 
executed well within the tolerance of late responding normal 
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tissues. Higher total dose translates into a higher biological 
effective dose. Other rationales are radio sensitization through 
redistribution and lesser dependence on oxygen effect. More the 
number of fractions, greater are the chances that the tumour cells 
would be in radiosensitive phase in the next fraction. 
So our intent of using concurrent chemotherapy added to  
hyperfractionation in the treatment of advanced unresectable  Head 
and Neck squamous cell malignancies is to preserve organ function 
and to maximize local tumor control. This enhanced control is 
expected to translate as a survival benefit as evidenced from a 
number of previous studies.  
Careful patient selection, monitoring of the patient’s general 
condition and emotional balance throughout the treatment enable 
better compliance to treatment completion. Patients’ motivation to 
undergo the six week journey of chemo radiation along with proper 
counseling and disease education are very crucial.  
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REVIEW OF LITERATURE 
COMPARISION OF HYPERFRACTIONATED 
RADIOTHERAPY TO CONVENTIONAL RADIOTHERAPY 
Hyperfractionation has been extensively studied in varied 
setting like head and neck cancers, bladder cancer, lung cancer, 
rhabdomyosarcoma, whole brain radiotherapy for brain metastasis 
and acute lymphoblastic leukemia. But most striking results were 
obtained from head and neck malignancies. 
By addition of chemotherapeutic agents better 
radiosensitisation is aimed at and it directly manifests as improved 
oncological outcome. Dose escalation is achieved at the cost of 
increased acute toxicities. 
As early as in 1978, the results of RTOG 77-03 by     Marks 
R 
[31] 
concluded that hyperfractionated radiotherapy (66 Gy in  1.25 
Gy BID) gave adequate tumor control, with acceptable acute and 
late toxicity. Dose greater than 1.5 Gy BID was too toxic, and 
required treatment breaks. 
In 1987, Marcial et al 
[34] 
reported the results of RTOG 79-13 
(1979-1983). The study randomized 187 patients of Stage III-IV or 
T2N0 base of tongue, nasopharynx, and maxillary sinus to receive 
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either conventional radiotherapy  66 Gy to 73.8 Gy in 1.8-2 
Gy/fraction once daily or  hyperfractionated  radiotherapy 60 Gy in 
1.2 Gy BID, 3-6 hrs apart. The 2 year locoregional control rate with 
conventional radiotherapy was 29% and with hyperfractionated 
radiotherapy was 30% (not statistically significant).More acute 
reactions were reported from hyperfractionated radiotherapy arm. 
Late reactions were similar between the two arms. 
In 1992, Horiot et al 
[24]
analyzed the EORTC 22791 
[35] 
(1980-1987) study results of  356 oropharyngeal cancers of stage 
T2- N0-1 (base of tongue and size < 3 cm lesions were 
excluded).The patients were randomized to receive  either 
conventional radiotherapy  70 Gy in 7-8 weeks or pure 
hyperfractionated radiotherapy 80.5 Gy in 1.15 Gy fractionation 
twice daily. Hyperfractionation arm showed a higher local disease 
free survival (59%) compared to conventional fractionation (40%). 
Hyperfractionation arm also showed an improvement in overall 
survival (p=0.08) .T3 tumors especially responded well to 
hyperfractionation. No difference was observed in late effects.  
In 1993,Parson et al 
[32] 
from University of Florida showed a 
improved locoregional control for 419 patients of   T2 to T4 
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squamous cell carcinoma of the head and neck  treated with twice-
a-day radiotherapy (1.2 Gy BID to 74.4 -79.2 Gy).  
PHASE III TRIALS OF HYPERFRACTIONATED 
RADIOTHERAPY 
Outcomes 
Study 
arms 
Pinto et 
al[25] 
Fu et al [26] 
(2000) 
Cummings 
et al(2000) 
 
Dose/fraction 
Arm 1 1.1 Gy BD 1.2   Gy BD 1.45 Gy BD 
Arm 2 2 Gy OD 2  Gy OD 2.55 Gy OD 
 
Total dose 
Arm 1 70.4 Gy 81.6 Gy 58 Gy 
Arm 2 66 Gy 72    Gy 51 Gy 
 
Overall time 
Arm 1 6.5 weeks 6  weeks 4 weeks 
Arm 2 6.5 weeks 7  weeks 4 weeks 
LCR 
Arm 1 84% 
Higher in Hyper 
fractionation 
arm P=0.04) 
45% 
Arm 2 
64% 
(p=0.02) 
37% 
(p=0.01) 
 
 
Overall 
survival rate 
Arm 1 27%(3 yr) 
No Difference 
In OS 
40%(5 yr) 
Arm 2 
8 
%(p=0.03) 
30% 
(p=0.01) 
Side effects  
Early acute 
reactions 
More mucositis with HF, No 
difference in late complication 
rate. 
All the following trials say hyper fractionated radiotherapy is 
better when compared to conventional fractionation. 
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COMPARISION STUDY OF HYPERFRACTIONATED 
RADIOTHERAPY WITH OTHER ALTERED 
FRACTIONATION SCHEDULES 
Between 1991 to 1997 ,a phase III randomized study RTOG 
90-03 
[38] 
compared standard fractionation, hyperfractionation, split 
course accelerated fractionation and accelerated fractionation with 
concomitant boost. 1073 patients of Stage III-IV (oral cavity, 
oropharynx, or supraglottic larynx) or Stage II-IV (base of tongue, 
hypopharynx) were  randomized into 4 arms. 
Arm 1.  Conventional fractionation 70 Gy in 35 fractions (2 
Gy/fraction) 
Arm 2. Hyperfractionation 81.6 Gy in 68 fractions (1.2 Gy BID)  
Arm 3. Split course accelerated fractionation 67.2 Gy in 42 
fractions (1.6 Gy BID) with 2 week break after 38.4 Gy  
 Arm 4. Concomitant boost 72 Gy given 54 Gy in 30 
fractions (1.8 Gy OD) + 18 Gy in 12 fractions (1.5 Gy concurrent 
BID boost)  
There were increased acute effects but no increase in late 
effects. So he concluded that hyperfractionation or Concomitant 
Boost improved locoregional control when compared to standard 
fractionation. 
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RESULTS OF RTOG 90-03 
outcomes 
Standard 
fractionation 
Hyper 
fractionation 
Accelerated 
fractionation 
with split 
course 
Accelerated 
concomitant 
boost 
2 Year 
DFS 
32% 38% 33% 39% 
5 Year 
DFS 
21.2% 30.7% 26.6% 28.9% 
2 Year 
OS 
46% 54% 46% 51% 
5year OS 29.5% 37.1% 30.8% 33.5% 
Local 
Failure 
44% 38% 43% 37% 
Regional 
Failure 
32% 27% 31% 33% 
DFS-disease free survival; OS-overall survival 
There was no impact on disease free survival and overall 
survival. Split course was comparable to standard fractionation. In 
2005, Trotti 
[33] 
reported the 5 year follow up in ASTRO. He 
showed a trend for increase in grade 3+ late effects with AFX-CB 
(p=0.066).TWIST analysis done in the RTOG study group in 2008 
showed quality adjusted survival was better only for 
hyperfractionation and not for accelerated fractionation. 
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IMPACT OF NUTRITION 
In 2006,   Rabinovitch 
[36]
 did a secondary analysis on the 
impact of nutrition in the RTOG 90-03 patients. Patients who were 
in nutritional support even before treatment attained inferior 
outcomes.  
RTOG 83-13 studied dose escalation with hyperfractionation 
between 1983 and 1987 in a phase II randomized trial. 451 patients 
of advanced head and neck cancer were treated with 
hyperfractionation 1.2 Gy BID, 4 hrs apart, up to 67.2 Gy; 72.0 Gy 
and 76.8 Gy in each arm.  
2-year locoregional control showed improvement with dose 
escalation [25% vs. 37% vs. 42% (p=0.08)] 2-year Grade 4 necrosis 
reported was 10% vs. 5% vs. 14% respectively.  
5 year follow up of RTOG 83-13 reported that there is no 
difference in late toxicity between the dose escalated 
hyperfractionation groups and that the ideal interfractionation 
interval should be >4.5 hours. 
In 1986, EORTC 22811 compared  hyperfractionation with 
or without hypoxic cell sensitisers like misonidazole with 
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conventional radiotherapy . There was no difference in survival or 
local control with addition of misonidazole. 
CONCURRENT CHEMOTHERAPY IN ADDING UP HYPER 
FRACTIONATED RADIOTHERAPY 
SINGLE AGENT CHEMOTHERAPY 
A low dose of cisplatin was added to hyperfractionation by 
Denham et al. Various sites and stage III – IV cancers were 
treated. 
 Arm 1: 77 Gy/7 wk + Cisplatin (6 mg/m2/d) 
 Arm 2: 77 Gy/7 wk (1.1 Gy, bd.) 
5-year Progression Free Survival: 46% vs. 25% (p = 0.007); 
5-year Distant Metastasis Free Survival: 86% vs. 57% (p = 0.001) 
and 5-year Overall Survival: 46% vs. 25%. (p = 0.008). There were 
no significant difference in acute toxicities (except for leucopenia, 
p = 0.006) or late toxicity. 
In 2000, Jeremic et al. 
[14]
 conducted a randomized trial in 
hyper fractionation with chemotherapy in 130 stage III and IV 
patients and found improvement in all oncological outcomes .This 
was a true therapeutic gain because there was no difference in late 
side effects. Results are as tabulated. 
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  RESULTS OF HYPER FRACTIONATION WITH 
CHEMOTHERAPY JEREMIC ET AL 
Outcomes 
HFX with Chemo (low-dose 
daily cisplatin + 77 Gy /1.1 Gy 
/ fraction BD) 
HFX 77 Gy / 1.1 
Gy / fraction twice 
daily 
LRC 50% 36%;       P=0.04 
5-year PFS 46% 25%;       P=0.007 
5-year 
DMFS 
86% 
57%;       p = 0.001 
 
5-year OS 46% 25%;      p = 0.008 
HFX-HyperFractionation; LRC-LocoRegionalControl; PFS-
Progression Free Survival; DMFS-Distant Metastasis Free Survival; 
OS-Overall Survival 
Also there is a report from Zurich which randomized 224 
patients with squamous cell carcinoma as follows: 
Arm-1:  2 cycles of  Cisplatin 20 mg/m
2
 on 5 days of weeks 1 
and 5 + Hyperfractionated  radiotherapy  (74.4 Gy in 1.2 Gy twice daily) 
Arm2:   Hyperfractionation  74.4 Gy in 1.2 Gy twice daily only. 
Loco regional control (p=0.039) and distant disease-free 
survival (p = 0.011) were significantly improved with concurrent 
Cisplatin with hyper fractionation. There was no difference in 
overall survival and similar late toxicity.  
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In 2004, Heguenin P et al,
 [30]
 (Swiss trial) randomized 
advanced head and neck cancer patients to hyperfractionated 
radiotherapy 1.2 Gy twice daily up to 74.4 Gy with or without 2 
cycles of concurrent Cisplatin 20 mg/m
2
 on days 1 to 5 of weeks 1 
and 5. He reported an improvement in the locoregional control rate 
and distant disease free survival but there was no difference in 
overall survival. 
MULTI AGENT MODALITY CHEMOTHERAPY 
CONCURRENT WITH HYPERFRACTIONATION 
German Cancer Society compared hyper fractionated 
accelerated radiotherapy with concurrent chemotherapy with dose 
escalated hyperfractionated accelerated radiation.  84 patients with 
stage III  and IV head and neck cancer were randomized. 
Arm-1: Concurrent chemotherapy and Hyper fractionated 
accelerated radiotherapy to 70.6 Gy in 6 weeks 
Arm-2: Hyperfractionated  accelerated radiation alone to 77.6 Gy 
CHEMOTHERAPY 
5-fluoroucil (600 mg/m
2
IV continuous infusion for 120 hours) 
on days 1-5 and  Mitomycin (10 mg/m
2
) on days 5, 36.        
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  GERMAN CANCER SOCIETY TRIAL RESULTS 
Disease outcomes 
Hyper  
fractionation with 
chemotherapy 
Hyper 
fractionation 
alone 
5 yr loco regional 
control 
49.9% 37.4% (p = 0.001) 
5 yr overall survival 28.6% 23.7% (p=0.023) 
Progression-free 
rate 
29.3% 26.6% (p = 0.009) 
freedom from  
metastases rates 
51.9% 54.7% (p = 0.575) 
There were no differences in late reactions.   
Brizel et al  
[29] 
compared hyperfractionated radiotherapy 
alone 75 Gy in 60 twice daily fractionation with hyperfractionated  
radiotherapy (70 Gy in 56 twice daily fractions with a 7 day split in 
between) with concurrent chemotherapy. 2 cycles of concurrent 
Cisplatin 12 mg/m2 and 5 FU 600 mg /m2 day 1 to 5 was given 
concurrently with radiation and 2 more cycles of the same 
chemotherapy was used as maintenance. 
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BRIZEL ET AL STUDY RESULTS OF HYPERFRACTIONATED 
RADIOTHERAPY AND CHEMOTHERAPY 
Outcomes 
Hyperfractionation 
alone 
Hyperfractionation 
and CDDP+5FU 
3 YEAR 
LOCOREGIONAL 
CONTROL RATE 
40% 70%  (p=0.01) 
RELAPSE FREE 
SURVIVAL RATE 
41% 61% (p=0.08) 
OVERALL 
SURVIVAL RATE 
34% 55% (p=0.07) 
RESULTS OF METAANALYSIS OF HYPERFRACTIONATED 
CHEMORADIOTHERAPY 
In Sept 2006 MARCH Collaborative group, reported the 
results of a  meta-analysis of head and neck cancers patients treated 
with chemoradiotherapy. A total of 15 trials were analyzed .Study 
population included 6515 patients. A median follow up 6 years was 
done. Oropharynx and larynx cancers were most common subsites 
treated.74% of the study population belonged to stage III and IV. 
The analysis showed an overall survival benefit with altered 
fractionation schedules. An absolute benefit 3.4% at 5 years; HR= 
0.92, 95% CI 0.86-0.97,p=0.003 was observed. 
There was a significantly higher benefit with hyper 
fractionation 8% at 5 years. Locoregional control with altered 
fractionation was better than conventional  radiation 6.4% at 5 
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years (p<0.0001). Benefit observed was less in older patients aged 
> 70 years. 
In the meta analysis conducted by Budach et al  
[19]
combined 
chemotherapy with altered fractionation was studied. 32 trials were 
studied and 10225 patients were analyzed. Overall survival benefit 
of 12 months was observed with addition of chemotherapy to 
conventional/ altered fractionation (p<0.001). There was a 
substantial prolongation of median survival of 14.2months with 
hyperfractionation compared to conventional RT. 
In 2007,   Bourhis et al  
[27]
analyzed  120 randomised trials 
comprising of  25,000 patients. A median follow up to 6years was 
done. He reported  that an addition of chemotherapy to hyper 
fractionation and accelerated fractionation regime improved  
locoregional control and survival outcome compared with  only 
radiation. Other reported acute toxicities and  long term toxicities  
were comparable. 
They concluded that concurrent chemotherapy with Hyper 
fractionated accelerated radiotherapy to 70.6 Gy was superior to 
dose-escalated hyperfractionated radiotherapy to 77.6 Gy with less 
acute reactions and equivalent late reactions. 
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The MACH-NC meta-analysis says for patients who undergo 
a non surgical treatment, concurrent chemoradiation is the standard. 
The UKHAN 1 trial also confirms this. The UKHAN 1
[21]
 study 
also says long term benefit in terms of reduced recurrence and 
deaths can be achieved with non – platinum agents.  
So using hyperfractionated radiotherapy with a chemotherapy  
a non platinum agent ( Docetaxel) is a novel protocol to treat the 
unfavourable locally advanced and unresectable squamous cell 
carcinomas of head and neck. 
CONCURRENT CHEMOTHERAPY DOCETAXEL  WITH 
HYPERFRACTIONATION  
Karasawa et al studied hyperfractioned radiotherapy with 
Docetaxel in  70 patients treated with 1.2gy per fraction. 
Oropharynx 25, hypopharynx 2, larynx 18 an other sites 3 were 
studied. Median follow up was 43 months and 5 year local control 
rate = 62.6%,Over all survival rate 61.6% with acceptable toxicity.  
Fumihiko et al had studied and analysed in 25 patients of locally 
advanced  head and neck carcinoma treated with hyperfractionated 
radiotherapy and weekly docetaxel  shows complete response in the 
primary is 84%,complete response in secondary is 61% and the overall 
response rate is 68% with minimal toxicities. 
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AIM OF THE STUDY   
To assess the immediate loco regional response rates of 
locally advanced unresectable squamous cell carcinomas of the 
head and neck treated with hyperfractionated radiotherapy and 
concurrent weekly Docetaxel  
OBJECTIVE(S)  
 To assess acute toxicity to the treatment. 
 To assess the prognostic factors which determine the response 
to treatment. 
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MATERIALS AND METHODS 
TYPE OF THE STUDY 
Cross Sectional Study 
DURATION 
March 2015to September 2015 
NUMBER OF PATIENTS 
30 
PATIENT INFORMED CONSENT 
All patients were given an information sheet detailing the full 
course of the study protocol. Informed consent was obtained from 
them in the local language (Tamil) which was specially made to 
serve the purpose. Hand outs explaining the do’s and dont’s during 
radiotherapy with explanations about the oral care, dental care, skin 
care and nutritional care were made available to them. Institutional 
ethical committee clearance was obtained. 
PATIENT SELECTION 
Patients with stage III and IV unresectable squamous cell 
carcinoma of head and neck were treated in this protocol.  
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INCLUSION CRITERIA 
 Biopsy proven newly diagnosed squamous cell carcinoma of 
the head & neck. 
 Tumours considered unresectable due to technical inability to 
obtain a clear margins. 
 Primary tumor sites: oral cavity, oropharynx, hypo pharynx, 
larynx.  
 Age >18 - 60 years 
 Stage III or IV (M0) nonmetastatic disease (AJCC staging 
manual 7
th
 edition ) 
 Previously untreated for the present malignancy 
 No prior history of cancer 
 No prior exposure to radiotherapy or chemotherapy 
 KPS>/=70% 
 No major life threatening co morbidities.  
EXCLUSION CRITERIA 
 Non Squamous Histopathology  
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 Tumours of nasal cavity, paranasal sinuses, nasopharynx and 
salivary gland . 
 Primary involving bone/cartilage 
 Recurrent tumours 
 Inadequate hepatic and renal functions, bone marrow reserve.  
 Patient not consenting to chemotherapy at any point in the 
treatment. 
 Previously received  treatment for any other malignancy 
(within past 5 yrs) 
 Pregnant females. 
WORK UP 
 Complete history and physical examination 
 Biopsy from tumour 
BLOOD INVETIGATIONS 
 Complete blood count WBC > 4000 /mm3  
 Haemoglobin >11% 
 Platelet count >1, 00,000/cu mm  
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 Serum Creatinine </=1.2mg/dl 
 Liver function tests: Serum Total Bilirubin </=1.2mg/dl  
 Blood Grouping and Typing 
RADIOLOGICAL IMAGING 
CT scan Neck (From base of skull to Root of Neck) – Plain 
and Contrast pre-treatment and post treatment). 
 Pan Endoscopy 
 Cardiac evaluation:  ECHO cardiogram, ECG, chest X-ray 
 Weekly CBC, RFT before each course of chemotherapy  
 Staging is done based on American Joint Committee staging 
manual 7
th
 edition (for head and neck cancers). 
PRETREATMENT PATIENT PREPARATION 
ORAL CARE 
Mucositis is the most important therapy limiting toxicity in 
head and neck cancer treatment. An indigenously prepared solution 
by dissolving three tablespoons of soda bicarbonate and three 
tablespoons of table salt (sodium chloride) in 1 gallon of distilled 
water was used for mouth gargle. Patients were asked to gargle ten 
times a day, especially after food. Patients who developed oral 
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candidiasis were treated with tablet Fluconazole 100 mg po or 
Clotrimazole lozenges for 7 days. 
DENTAL CARE  
Prior to starting chemo radiation a thorough oral and dental 
evaluation was done in all eligible patients. Following dental 
prophylaxis a rest time of 2 weeks was given for proper healing of 
the gums over the extracted tooth and for any associated infection 
to subside. 
Advanced carries, tooth in a state of disrepair were extracted 
to minimize the risk of osteo radionecrosis. Impacted tooth may 
also be considered for extraction. Marginal tooth may be extracted 
to enable patients to maintain a good oral hygiene and better 
nutrition. 
Nature of salivary secretions is altered due to irradiation of 
major and minor salivary glands. This reduces the buffering ability 
and pH of saliva and enhances debris and plaque formation over the 
tooth .Radiation itself causes hypocalcification of tooth. So daily 
cleaning with a fluoride containing toothpaste, flossing, and soft 
brushing were done during and after radiotherapy.  
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NUTRITIONAL SUPPORT  
Treatment related weight loss is known to occur in head and 
neck chemoradiation due to the disease per se or treatment related 
toxicities. Nutritional interventions like nasogastric tubes, 
percutaneous endoscopic gastrostomy tubes and intravenous 
nutritional support were offered to patients for whom enteral 
feeding was not feasible to combat the caloric requirements.  
The NCCN 2012 panel does not recommend prophylactic 
nasogastric tube or gastrostomy tube placement for patients in good 
performance status without pretreatment weight loss, severe airway 
obstruction or dysphagia.  
SMOKING CESSATION 
Elevated interest to quit smoking was used an opportunity to 
intervene and provide assistance in the quitting process.  
A proposed mechanism of biological interaction of radiation 
and smoking by Grau et al hypothesize that the hypoxia caused by 
high levels of carboxyheamoglobin in smokers correlate with the 
poor oncological outcome.         
Nicotine also interferes with the chemotherapeutic efficacy 
by inducing resistance to chemotherapy induced apoptosis by 
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modulating the mitochondrial signaling. Treatment related adverse 
side effects like mucositis, xerostomia, poor voice quality, 
disfigurement are higher in patients who continue to smoke.  
MULTIDISCIPLINARY TEAM 
All patients had access to full range of specialists and support 
services with expertise in the management of head and neck cancers 
for optimal treatment and follow up. Specialized nursing care, 
speech and swallowing therapy, nutrition support, psychiatry, 
deaddiction services, audiology and palliative care were made 
available. 
TREATMENT 
All patients were treated as inpatients to enable them to 
receive the twice daily radiation and six weekly chemotherapy 
cycles. 
PROTOCOL  
30 patients with locally advanced unresectable squamous cell 
carcinomas of the head and neck satisfying the inclusion criteria 
after completion of the pretreatment work up and preparation as 
mentioned earlier were treated with hyperfractionated radiotherapy 
and  weekly docetaxel . 
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RADIOTHERAPY PLANNING 
A total planned dose of 72 Gy was delivered in 120 cGy per 
fraction; two fractions per day at 6 hours interval,  to the 
selected treatment fields. Patients received radiation 5 days a week 
and chemotherapy was given in between the two radiation fractions. 
Radiation was given using a cobalt 60 Theratron Phoenix machine 
at 80 cm SSD. 
RADIATION DOSAGE 
Patients were treated from Monday to Friday of the week. 
Each day they receive 120 cGy twice so that they achieve 2.4 Gy 
per day. Similarly they receive radiation for 6 weeks. 
Hyperfractionated radiotherapy treatment was complete by 6 weeks. 
Dose received per week is 12 Gy as opposed to conventional 
radiotherapy where the dose is 10 Gy per week. 
RADIATIONFIELDS 
Initial treatment field included the primary tumor plus 2 cm 
margin, clinically involved secondary lymph nodes and the lymph 
nodes probable to lodge the occult microscopic disease in the 
drainage area. Uninvolved lymph nodal stations received 50.4 Gy 
(21 fractions) while the clinically involved nodes proceed up to the 
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final dose as for the primary. Dose was calculated in the midplane 
for opposing lateral fields. 
RADIATION PORTALS 
 All patients were treated with opposed lateral fields and 
appropriate shielding of the spinal cord was done after 45 Gy  as 
per the institutional policy. 
VERIFICATION 
All treated patients were placed in treatment position and 
simulated. The treatment portals were verified and corrections were 
made. 
DOSE CONSTRAINTS 
Tolerance dose of spinal cord is 45 Gy in conventional 
fractionation for a length of 5 to 10 cm. Parotid is tolerant up to 26 
Gy after which permanent xerostomia is expected to occur.  
CHEMOTHERAPY 
Injection docetaxel 20 mg /m 
2
was given on every Monday, 
weekly for a total of 6 courses inbetween the two fractions.  
PREMEDICATION  
Pre hydration with one litre of normal saline  is done for two 
hours. 
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Premedication given 30 minutes before chemotherapy is as follows  
 Injection Ranitidine 50 mg IV 
 Injection Dexamethasone 20 mg 12 hr, 6 hr and immediately 
(30 minutes) before administration of  docetaxel  
 Injection Pheneramine maleate 45.5 mg IV  
 Injection Ondansetron 8 mg IV 
Injection docetaxel 20 mg /m
2
 is mixed in 500 ml of normal 
saline and infused in intravenous codon set with extravasation 
precautions. Following this 500ml of normal saline is again infused 
for one hour. 
Every week blood investigations were repeated before 
chemotherapy. Any fall in blood parameter like haemoglobin was 
corrected by blood transfusion; colony stimulating factor was 
proposed to be used when the Absolute Neutrophil Count[ ANC = 
(segmented neutrophils% + segmented bands%)/ 100 x WBC count 
in multiples of 1000s]  would fall below 1000 cells/cubic 
millimetre and only symptomatic thrombocytopenia  was corrected 
by platelet transfusion. Entire treatment is to be completed in 6 to 7 
weeks ideally. 
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PATIENT CARE DURING CHEMORADIATION 
TOXICITY ASSESSMENT 
Patients are reviewed every day before radiation. Firstly, 
attention was given to the maintenance of a good oral hygiene. 
Good hydration status of the patient was ensured. Local toxic 
reactions like epilation, skin reactions, dysphagia, laryngitis, 
xerostomia and mucositis were recorded and graded. Radiation was 
suspended once patient developed grade 3 or above acute reactions. 
Also adequacy of the daily calorific value of food was ensured.      
Hematological parameters were looked into every week 
before the weekly dose of chemotherapy. Any level of haemoglobin 
less than 10 gm/dl was corrected by packed red cell transfusion. 
WBC and platelet counts were also checked. 
RESPONSE EVALUATION 
Patients were reassessed with CT Neck 4 -6 weeks after 
completing chemo radiation. 
 Tumor response as defined by Response Evaluation Criteria 
in Solid Tumors (RECIST 1.1 version) Criteria 
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 Complete Response: Disappearance of all target lesions; 
malignant nodes <10 mm. 
 Partial Response: At least 50% reduction in the sum of the 
longest diameter of target lesions, taking as reference the 
baseline study; confirmed at 4 weeks. 
 Stable Disease: Neither partial response nor progressive 
disease criteria are met, in a minimum time set by the 
protocol 
 Progressive Disease: At least 20% increase in the sum of the 
diameter, with a minimum absolute increase of 5 mm, taking 
as reference the  smallest sum in the study or appearance of 
new lesions. 
FOLLOW UP 
Patients were discharged a week after completion of 
chemoradiotherapy or complete recuperation whichever is earlier.  
They were reviewed with a CT neck plain and contrast 
4weeks after completion of chemoradiotherapy for response 
assessment. Response evaluation was done using RECIST criteria 
as mentioned above. 
 43 
Chest imaging, dental evaluation, hearing evaluation were 
done as clinically indicated. Continued smoking cessation, 
rehabilitation, speech and swallowing therapy were offered.  
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RESULTS 
30 patients who satisfied the inclusion criteria were accrued 
to the study from March 2015 to September 2015.Patients 
underwent treatment as per protocol. 30 patients completed the 
planned course of chemotherapy and radiotherapy.  
PATIENT CHARACTERISTICS 
1.Age Distribution 
30 patients were enrolled into the study. 
 Table 5.1.Age Distribution 
Age Group No. of  Patients Percentage (%) 
11 to 20 years 0 0 
21 to 30 years 0 0 
31 to 40 years 7 23.33% 
41 to 50 years 15 50% 
51 to 60 years 8 26.66% 
Median age of the study population is 45.03 years. Age 
groups ranged from 31 to 59 years.50% of the study population 
were between 41 to 50 years of age group. 
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2.GENDER 
Male patients outnumbered females.28 of the study 
population were male and 2 were female. 
 Table-5.2: Gender Distribution 
Gender No. Of patients Percentage (%) 
Male 28 93.33% 
Female 2 6.66% 
3. KARNOFSKY PERFORMANCE STATUS: 
Hyperfractionation with  chemotherapy is a challenging 
treatment protocol which mandates good performance status. 
70%patients were in  KPS score of 90; 13.33% patients were in 
performance score 80 and 16.66% patients in score 70. 
Table 5.3.Karnofsky Performance Status 
SCORE NO. OF PATIENTS PERCENTAGE (%) 
90 21 70% 
80 4 13.33% 
70 5 16.66% 
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4. HABITS: 
33.33% of the study population used smokeless tobacco and 
alcohol; 26.66% used smoking forms of tobacco and alcohol;6.67 % 
had smoking habit only; 10% used smokeless tobacco only; 10% 
used alcohol only and  13.33% had all three habits.  
17 patients (56.66% ) used smokeless tobacco either alone or 
in combination with smoking and alcoholism .This high incidence 
of smokeless tobacco usage  is associated mostly with oral cavity 
cancers which constitutes a third of our study population.  
Table 5.4.Habits 
Habits 
No. Of 
patients 
Percentage (%) 
Smoking+smokeless tobacco 
usage+alcoholism 
4 13.33% 
Smoking and smokeless tobacco 
usage 
0 0 
Smoking and alcoholism 8 26.66% 
Smokless tobacco use+alcoholism 10 33.33% 
Smoking only 2 6.67% 
Smokeless tobacco use only 3 10% 
Alcoholism only 3 10% 
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5. SUBSITE DISTRIBUTION: 
Most of patients had primary in oropharynx (40%) and oral 
cavity (36.66%) followed by larynx (20%) and then hypopharynx 
(3.33%).  One patient each in the oral cavity (T3 N3) group and the 
oropharyngeal group (T4a N3) could not complete the planned 
treatment.               
 Table 5.5   Subsite Distribution 
Subsite No. Of patients Percentage 
Cancer oral cavity 11 36.66% 
Cancer oropharynx 12 40% 
Cancer hypopharynx 1 3.33% 
Cancer larynx 6 20% 
6. PRIMARY TUMOR CHARACTERISTICS  
 66.66% patients had in T3 tumors and 33.33% had T4a 
tumors. None of the patients had T4b tumor.   
Table 5.6 Primary Tumor Characteristics   
T stage No. Of patients Percentage 
T3 20 66.66% 
T4a 10 33.33% 
T4b 0 0 
 
 48 
7. SECONDARY NODE CHARACTERISTICS 
20% patients had N0, 33.33% patients had N1 nodes, 40% 
patients had N2 nodes and 6.67% patients had N3 nodes.           
Table 5.7 Secondary nodal characteristics 
N stage No. Of patients Percentage 
N0 2 6.67% 
N1 12 40% 
N2 15 50% 
N3 1 3.33% 
8. HISTOLOGICAL DIFFERENTIATION OF THE PRIMARY  
Most of the study population 56.66%  had  moderately 
differentiated;36.67% had  well differentiated cancers and 6.67% 
had poorly differentiated cancers. 
Table 5.8 Histological differentiation of the primary 
Differentiation No. Of patients Percentage 
Well differentiated 11 36.67% 
Moderately 
differentiated 
17 56.66% 
Poorly differentiated 2 6.67% 
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9. STAGE GROUPING 
The stage grouping distribution shows most of the patients 
were in the locally advanced stages like stage III and stage IV A.  
Table 5.9 Stage Grouping 
 T1 T2 T3 T4a T4b TOTAL 
N0 0 0 2(6.67%) 0 0 2(6.67%) 
N1 0 0 8(26.67%) 4(13.33%) 0 12(40%) 
N2a 0 0 2(6.67%) 0 0 2(6.67%) 
N2b 0 0 1(3.33%) 1(3.33%) 0 2(6.66%) 
N2c 0 0 6(20%) 5(16.67%) 0 11(36.67%) 
N3 0 0 1(3.33%) 0 0 1(3.33%) 
Total 0 0 20(66.67%) 10(33.33%) 0 30(100%) 
 
 50 
10. STAGEWISE DISTRIBUTION 
46.67% patients were grouped as stage III, 50% patients as 
stage IV A, and 3.33% patients in stage IV B. 
Table 5.10.Stage wise Distribution 
Stage No.of patients Percentage 
STAGE III 10 33.33% 
STAGE IV A 19 63.33% 
STAGE IV B 1 3.33% 
11. CHEMOTHERAPY CYCLES RECEIVED 
Table 5.11.Chemotherapy cycles received 
No. Of chemotherapy 
cycles received 
No. Of 
patients 
Percentage 
1  CYCLE 0 0 
2 CYCLES 0 0 
3 CYCLES 0 0 
4 CYCLES 1 3.33% 
5 CYCLES 12 40% 
6 CYCLES 17 56.67% 
56.67% patients completed 6 cycles, 40% completed 5 cycles, 
and 3.33% patients received only 4 cycles of chemotherapy. The 
major toxicity encountered to suspend one or two cycles 
chemotherapy was the intense grade 3 mucositis during the last two 
weeks of radiation. 
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ACUTE LOCAL REACTIONS 
Acute reactions like mucositis, skin reactions, dysphagia, 
xerostomia and laryngitis were scored by using   RTOG Acute 
Morbidity Scoring Criteria. 
13. MUCOSITIS 
Table 5.13. Mucositis 
MUCOSITIS NO. OF PATIENTS PERCENTAGE 
GRADE 0 0 0 
GRADE 1 0 0 
 GRADE  2 11 36.67% 
 GRADE  3 19 63.33% 
GRADE 4 0 0 
36.67%  patients had developed patchy mucositis grade 
63.33% patients had developed confluent mucositis (grade 3). 
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14. DYSPHAGIA  
63.33% patients had developed severe dysphagia (grade 3) 
required nasogastric tube feeding. Remaining 36.67% patients 
developed moderate dysphagia  (grade 2). 
  Table 5.14.  Dysphagia 
DYSPHAGIA NO. OF PATIENTS PERCENTAGE 
GRADE 0 0 0 
GRADE 1 1 3.33% 
GRADE 2 10 33.33% 
GRADE 3 19 63.33% 
GRADE 4 0 0 
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15. SKIN TOXICITY  
73.33% patients had patchy moist desquamation (grade 2); 
26.67% patients developed dry desquamation (grade 1); 3.33% 
patient had confluent moist desquamation (grade 3).  
Table 5.15. Skin Toxicity 
SKIN REACTIONS NO. OF PATIENTS PERCENTAGE 
GRADE  0 0 0 
GRADE  1 8 26.67% 
GRADE  2 21 73.33% 
GRADE  3 1 3.33% 
GRADE  4 0 0% 
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16. XEROSTOMIA 
Table 5.16.Xerostomia 
Toxicity of salivary 
gland 
No. Of patients Percentage 
GRADE  0 0 0 
GRADE1 21 73.33% 
GRADE  2 9 26.67% 
GRADE  3 0 0 
GRADE  4 0 0 
73.33 % of patients had dry mouth (grade 1) and thickened 
saliva and rest of the 26.67% of patients had moderate dryness and 
sticky saliva (grade 2). 
17. LARYNGITIS 
60% patients had mild hoarseness of voice (grade 1); 30% 
patients persistent hoarseness of voice (grade 2) and 10% patients 
developed whispered speech (grade 3). 
Table 5.17.Laryngitis 
Laryngitis No. Of patients Percentage 
GRADE  0 0 0 
GRADE  1 18 60% 
GRADE  2 9 30% 
GRADE  3 3 10% 
GRADE 4 0 0 
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SYSTEMIC TOXICITIES  
Grading of Nausea and vomiting by Common Terminology. 
CRITERIA FOR ADVERSE EVENTS CTCAE VERSION 4. 
18.NAUSEA:  
13.33% patients had loss of desire for food without alteration 
in food habit (grade 1); 33.33% patients had diminished oral intake 
without significant weight loss and dehydration due to nausea 
(grade 2) and 53.33% patients were put on nasogastric tube because 
of inadequate oral and fluid intake (grade 3 nausea)  
Table 5.18.  Nausea 
Nausea No.of patients Percentage 
GRADE 1 4 13.33% 
GRADE 2 10 33.33% 
GRADE 3 16 53.33% 
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19.VOMITING 
80% patients had once or twice vomiting during the day of 
chemotherapy (grade 1) and remaining patients had 3 to 5 episodes 
of vomiting in 24 hours. None had grade 3 vomiting (6 times)  
TABLE 5.19 Vomiting 
Vomiting No .of patients Percentage 
GRADE 1 24 80% 
GRADE 2 6 20% 
GRADE 3 0 0 
GARDE 4 0 0 
GRADE5 0 0 
HEMATOLOGICAL TOXICITY 
Assessed by the RTOG Acute Morbidity Scoring Criteria. 
20.ANEMIA 
10 patients had hemoglobin >11 gm%(  grade 0 anemia);16 
patients had a fall during treatment with hemoglobin between 9.5 
and 11 gm%(grade 1 anemia);4 patients developed a greater fall 
and their hemoglobin was between 7.5 and 9.4 gm%(grade 2).  
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Table 5.20.Anemia 
Anemia grade No. Of patients Percentage 
GRADE  0 10 33.33% 
GRADE 1 16 53.33% 
GRADE 2 4 13.33% 
GRADE 3 0 0 
21.LEUCOPENIA 
Table 5.21 Leucopenia 
Toxicity grade No. Of patients Percentage 
GRADE 0 26 86.67% 
GRADE 1 4 13.33% 
GRADE 2 0 0 
GRADE 3 0 0 
GRADE 4 0 0 
86.67% patients had Total counts ≥4000 cells/cubic 
millimeter (grade 0 leucopenia) and remaining 13.33% patients 
total counts between 3000 and <4000 cells /cubic millimeter (grade 
1 leucopenia). 
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22. THROMBOCYTOPENIA 
Table 5.22. Thrombocytopenia 
Toxicity grade No. Of patients Percentage 
GRADE 0 29 96.67% 
GRADE 1 1 3.33% 
GRADE 2 0 0 
GRADE 3 0 O 
GRADE 4 0 0 
96.67% patients had a normal platelet count >100,000 cells 
per cubic millimeter during treatment (grade 0) and 1patient had  
grade 1 thrombocytopenia (75,000 to 100,000 cells per cubic 
millimeter). 
PROGNOSTIC FACTORS DETERMINING THE TUMOR 
OUTCOME 
AGE: 
People aged more than 50 years achieved a higher complete 
response 80% compared to 73.32% for people less than or equal to 
50 years. Partial response was lower in the age group above 51 
years 20% as against 26.68% in lower age group. But this finding is 
not statistically significant. 
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GENDER 
Males had more complete response than partial response. 
Females showed more complete and no partial response. The 
finding is not statistically significant.  
STAGE 
Stage III patients had 80% complete   response. Stage IV 
patients had75% complete response and 25% had partial response.  
This finding is also not statistically significant. 
CHEMOTHERAPY 
Patients who received 6 cycles of chemotherapy showed 
76.47% complete response .  In patients who received 4- 5 cycles of 
chemotherapy had 76.92%   complete response. This is not 
statistically significant.  
DURATION OF RADIOTHERAPY 
Overall treatment time as per protocol was 42 days.33.33% 
patients were able to complete treatment with ~3 days treatment 
interruption. Patients who had completed treatment an overall 
treatment time of ≤45 days had 80% complete response and 20% 
partial response.  patients who were treated with a overall treatment 
time >45 days had 75% complete response.  Duration of radiation 
did not produce a statistically significant impact on response. 
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HISTOLOGICAL DIFFERENTIATION OF THE PRIMARY  
25 out of the 30 primaries showed a complete response 
(83.33%). Moderately differentiated cancer patients had better 
response to chemoradiation. Moderately differentiated cancers 
showed 88.24% complete response rates and 11.76% partial 
response rate; poorly differentiated cancers had 100% complete 
response rate and well differentiated tumors showed good response 
rate. This finding was statistically significant.  
Table 5.23.Histologic Differentiation and Tumor Response 
Differentiation Complete response Partail response 
Well differntiated 6(54.54%) 5(45.46%) 
Moderately 
differentiated 
15(88.23%) 2 (11.77%) 
Poorly differentiated 2 (100%) 0 
T STAGE AND RESPONSE 
T3 tumors produced 90% complete response and the poorest 
responses 70% were seen for T4a tumors.  
Table 5.25. T stage and response 
T stage Complete response Partial response 
T3 18(90%) 2(10%) 
T4a 7(70%) 3(30%) 
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N STAGE AND RESPONSE 
Better complete responses were seen in N0 and N1 nodes. 
Less complete responses were seen in N2 nodal disease. 
Table 5.26. N stage and response 
N stage Complete response Partial response 
N0 2(100%) 0 
N1 11(91%) 1(9%) 
N2a 1(50%) 1(50%) 
N2b 2(100%) 0 
N2c 7(63.64%) 4(36.36%) 
N3 0 1(100%) 
STAGE GROUPING AND RESPONSE 
From the table lower stages, the tumor have higher complete 
response. Response rate decreased  in higher stage groups. 
STAGE-II (T3 N0 and T3 N1) had 100%  response rate. 
STAGE IV A have  a mixed complete response rate between 50% 
and 100% 
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Table 5.27. Stage grouping and response 
Stage grouping Complete response Partial response 
T3N0 2(100%) 0 
T3N1 8(100%) 0 
T3 N2a 1(50%) 1(50%) 
T3 N2b 1(100%) 0 
T3 N2c 4(66.66%) 2(33.33%) 
T3 N3 0 1(100%) 
T4a N0 0 0 
T4a N1 3(75%) 1(25%) 
T4a N2b 1 0 
T4a N2c 3(60%) 2(40%) 
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TUMOR SUBSITE AND RESPONSE 
Complete response rate were seen in hypo pharyngeal cancers 
(100%) and oropharyngeal cancers (90%); oral cavity cancers had 
the least complete response (54.54%) 
5.28. Tumor subsite and response: 
Subsite Complete response Partial response 
Oropharynx 11(91.66%) 1(8.34%) 
Oral cavity 6(54.54%) 5(45.46%) 
Larynx 5(83.33%) 1(16.67%) 
Hypopharynx 1(100%) 0 
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DISCUSSION 
Long term benefits with conventional radiation therapy were 
not fully satisfied and have failure in local control. With advanced 
stages of head and neck cancer , the problems of intrinsic radio 
resistance, sublethal damage repair by tumor cells, hypoxia and 
tumor repopulation.    To aim at improved therapeutic ratio 
hyperfractionated or accelerated fractionation has been widely tried 
in various clinical setting. The combination of chemoradiotherapy  
with modified fractionation schedules improve the results of 
advanced head and neck cancer. 
Our study is designed at treatment of locoregionally advanced 
squamous cell carcinomas of head and neck with hyperfractionated 
radiotherapy and weekly docetaxel . 
RADIATION DOSE ESCALATION 
So we used a total dose of 72 Gy in a try to escalate the dose. 
Our study shows a dose acceleration from conventional 
radiotherapy by 9.09%. Theoretically dose escalation of 7% to 17% 
is feasible without crossing the tolerance limit of late reacting 
tissue. This dose escalation produces better local control by 8 to 
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20%. Overall survival advantage of 10% to 19% compared to 
conventional fractionation.  
COMPARISION OF TOTAL TREATMENT TIME AND 
RADIATION DOSE 
Overall treatment time in hyperfractionation only arm is 6.3 
weeks (79.2 Gy in 1.2 Gy bd) ; hyperfractionation with 
chemotherapy arm (present study 72 Gy in 1.2 Gy bd) is 6 weeks. 
So the difference in overall treatment time between the present 
study and the pure hyperfractionation is 5%. 
Similarly the difference in the total radiation dose between 
the pure hyperfractionation (79.2 Gy) and the present study (72 Gy) 
is 10%. 
So we infer that the present study is compliant with the 
standard definition of hyperfractionation in terms of both overall 
treatment time and total radiation dose. 
BIOLOGICAL EFFECTIVE DOSE 
Ionizing radiation hits the DNA of the cell single stranded 
and double stranded breaks occur. Single stranded breaks increase 
linearly the possibility of the cell not surviving(α cell kill) and 
double stranded breaks increase exponentially the failure of the cell 
to replicate(β cell kill).Thus the α/β values of early and late effects 
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are obtained. So α represents the log e of the cells killed per gray 
radiation whereas β is the log e of the cells killed per gray squared.  
The α/β considered for calculation of early reacting tissues like 
head and neck cancers is ~10 Gy and for late reacting normal 
tissues is ~3 Gy. 
Biological effective dose is  the total dose required to 
produce the same log cell kill as the schedule being studied with 
small number of fractions considering the inter fraction interval and 
the cell repopulation correction factor. Biological effective dose 
were calculated based on the radiobiological linear quadratic cell 
survival model . 
By using the BED formula we are able to find out the 
biological effectiveness of different radiotherapy schedule taking in 
to account the total dose, number of fractions, dose per single 
fraction, α/β values of tumor or normal tissue and the repopulation 
correction factor. 
The biological effective dose (BED) for the various 
fractionation schedule is calculated by the formula 
  (1+  d ) 
BED = D ×   ---------- 
     (/β) 
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When overall time factor is included, the formula is altered as follows 
BED = D × [1 +   d       ] - 0.693 × (T-Tk) 
         (α/β)              α × Tp 
where D is the total dose  
d is the dose per fraction 
T is the overall treatment time 
Tk  is the time to onset repopulation of tumor from the day of start 
of radiation 
Tp is the constant; doubling time up to the end of radiation  
Model assumed α = 0.35 Gy; Tk is21 days for tumor and 7 days for 
acute mucosa; Tp is 3 days for tumor and 2.5 days for mucosa. 
Early effects of the current study  
BED in Gy10   = 72 (1+1.2 ) 
    10 
BED in Gy10   = 80.64Gy10 
α/β = 10 for acutely reacting tissues like mucosa and tumor  
late effects of the current study is 
BED in Gy3   = 72 (1+1.2 ) 
    3 
BED in Gy3   = 100.8Gy3 
α/β = 3 for late complications 
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EQD is called as the equivalent dose in 2 Gy 
[37]
. It is 
defined as the total dose in 2 Gy that gives the equal log cell kill as 
the schedule studied.  
For an early-responding tissue, a BED in Gy10 must be 
divided by 1+2/10 = 1.2 to find its EQD 10 /2, using this ‘‘early’’ α/β 
ratio of 10 Gy. 
For a late-reacting tissue BED in Gy3 is divided by 1+2/3 
=1.67 to find its equivalent dose in 2 Gy fraction EDQ3 /2, using the 
same ‘‘late’’ α/β ratio, 3 Gy.  
CALCULATION WITH REPOPULATION CORRECTION  
Tk is21 days for tumor cells and 7 days for mucosa;  Tp is 3 
days for tumor and 2.5 days for mucosa. 
BED in Gy 10 for mucosa = 72 × [1 +   1.2       ] - 0.693 × (40-7) 
                                                                          (3)            
     = 0.35× 2.5 
    = 80.64- 26.13 
    = 54.51 Gy10 
EQD 10/2    = BED IN GY 10 / 1.2 
    =54.51/1.2 
    =45.42 Gy10/2 
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Also using BED formula we can calculate the log cell kill for 
the schedule studied by using the below formula 
Log 10 cell kill   =BED Gy 10 × 0.152 
So first we calculate BED in gy 10 for tumor,  
BED in Gy10 for tumor = 72 × [1 +   1.2       ] - 0.693 × (40-21) 
                                                                        (3)              
     = 0.35× 3 
    = 80.64 – 12.54 
    = 68.1 Gy10 
Log cell kill   = 68.1 × 0.152 
= 10.35 
11 log 10 -Log cell kill is the reduction of 10 
9 
cells in a gram 
of tissue to a chance of one cell in 100 tumors surviving the 
radiation. The best head and neck radiotherapy schedule delivers 11 
to 11.2 log 10 cell kill 
[37]
. 
CLINICAL INTERPRETATION OF THE RADIOBIOLOGICAL 
PARAMETERS 
By restraining the late BEDs equivalent to 70 Gy in 2 Gy 
fractions we avoid the major late complications in head and neck 
irradiation. The major limiting factor in dose escalation in any form 
of altered fractionation schedule are the acute tissue reactions like 
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mucositis and dysphagia. When a new radiotherapy schedule is to 
be tested the calculation using BED early and late effects; By using 
EQD 3/2 Gy formulae  able to know whether  the schedule is toxic 
or not.  
From the calculations it is evident that the present study 
fractionation schedule shows  
 The least late reacting normal tissue toxicity(100.8Gy3) 
 Biological effective dose for early reacting normal tissue 
(80.86 Gy10) like mucosa is comparable to those produced by 
conventional RT (79.2 Gy10). 
 Acute mucosal EQD is 45.42 Gy 10/2 which is well within 
the grey zone. 
 Log cell kill of hyperfractionated radiotherapy is 10.35 
and is higher than the conventional schedule.                                   
It is explained that our study using hyperfractionation 
produces a log cell kill greater than conventional radiation; a 
mucosal EQD2 well within the grey zone and a least late tissue 
reactions. 
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BIOLOGIC EFFECTIVE DOSE OF ACUTE AND LATE 
REACTING TISUES IN VARIOUS TREATMENT 
SCHEDULES 
Radiotherapy 
Fractionation 
Schedules 
total 
dose 
Gy 
overall 
treatment 
time 
(days) 
acute 
BED 
Gy10 
 
late 
BED 
Gy3 
acute 
mucosal 
EQDGy 
10/2 
log 
cell 
kill 
Conventional RT 
33×2 Gy 
66 45 79.2 110 44.22 10.13 
Strong 
Conventional 35× 
2 Gy 
70 47 84 116.7 44.26 10.26 
Accelerated 
concomitant boost 
30×1.8 Gy + 
12×1.5 Gy 
72 39 84.4 113.4 49.21 11.02 
Pure 
Hyperfractionated 
RT 68 × 1.2 Gy 
81.6 45 91.39 114.2 51.08 11.48 
Continuous 
Hyperfractionated 
Accelerated 
Radiotherapy 36 × 
1.5 Gy Tds/12 
Days 
54 12 62.1 81 48.45 10.34 
Our Study Chemo 
Hyperfractionation 
60 × 1.2 
72 40 80.86 100.8 
 
45.42 
 
10.35 
Acutely reacting normal tissues have rapid cell turnover and 
highly sensitive to radiation. Radiosensitivity of tumor tissue is like 
to those of acutely reacting normal tissues. Hyperfractionation is 
advantageous in the tumors with low fractionation sensitivity  by 
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α/β values that are greater than those for late reacting normal 
tissues. 
OUTCOMEANALYSIS 
Our study showed a acceptable toxicity and high response 
rate similar to other hyperfractionation studies by Pinto et al, 
1991;Horiot et al, 1992; Cummings et al, 1996; Fu et al, 2000 and 
Jeremic et al, 2000.The overall response rates assessed at the end of 
6 weeks of hyperfractionated radiochemotherapy in our study is 
100% .Complete response rate of 62% achieved in our study. 
Also the most essential finding from our study is that 
hyperfractionated radiochemotherapy is enormously beneficial to 
the subset of patients with advanced primary and nodal disease as 
in opposition to the conventional fractionation; which is also more 
beneficial in treating the earlier stage disease. 
TO SUM UP 
 Female sex showed higher complete responses than male.  
 Stage-III Cancers Shows Higher Complete Responses Than 
Stage Iv A 
 Moderately and poorly differentiated cancers showed a 
considerable  complete response. 
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 Lower the t stage higher is the complete response 
 Lower the n stage higher is the complete response 
 Lower the tnm stage group higher is the complete response. 
 Hypopharyngeal and oropharyngeal tumors  produced 
greater complete response. 
 Complete response rate in primary T3 and T4a tumors are 
90% and 70% respectively. 
 Complete response rates attained by N0, N1, N2a, and N2c 
nodes are 100%, 90%, 50% and 63% respectively.  
 Primary and secondary complete response was achieved 
by 76% 
 High complete responses were achieved by T3N0 (1000%), 
T3 N1 (100%), then by T3N2a(50%),T3 N2c (66.66%),T4a 
N1 (70%) and last by T4a N2c (60%) 
SIDE EFFECTS 
 63.33% had grade 3 mucositis.     
 73.33% had grade 2 and 3.33% had grade 3 skin  toxicities 
 10% had grade 3 laryngitis. 
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 No Grade 3, 4 hematological toxicities in anemia 
 No Grade 3, 4 hematological toxicities in leucopenia or 
thrombocytopenia were observed. 
 There was no grade III or IV vomiting. 
LIMITATIONS 
Limitations of the study were the treatment delivery with 
cobalt 60- machine; the small number of study population. There is 
no powerful consensus for altered fractionation like 
hyperfractionation with chemotherapy.  
This protocol needs to be tested in a larger patient population 
in a phase III randomized control trial. 
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CONCLUSION 
Our study shows complete response rate (76.66%) this results 
are comparable with other international studies as mention in the 
literature. 30 patients completed the planned chemoradiotherapy 
with minimal treatment interruptions. Acute toxicities were 
acceptable and manageable. Differentiation of the primary lesions 
considerably influences the outcome. 
From our study, treatment protocol of loco regionally 
advanced unresectable squamous cell carcinomas of head and neck 
with concurrent weekly docetaxel 20 mg / m
2 
 is tolerable and 
feasible in our population.  
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ANNEXURE I 
RTOG - ACUTE RADIATION MORBIDITY SCORING CRITERIA 
Grade  0 1 2 3 4 
SKIN No 
change 
over 
baseline 
Follicular, faint 
or dull erythema/ 
epilation/dry 
desquamation/ 
decreased 
sweating 
Tender or 
bright 
erythema, 
patchy moist 
desquamation/ 
moderate 
edema 
Confluent, 
moist 
desquamation 
other than 
skin folds, 
pitting edema 
Ulceration, 
hemorrhage, 
necrosis 
mucous 
membrane 
No 
change 
over 
baseline 
Injection/ may 
experience mild 
pain not 
requiring 
analgesic 
Patchy 
mucositis 
which may 
produce an 
inflammatory 
serosanguinitis 
discharge/ 
may 
experience 
moderate pain 
requiring 
analgesia 
Confluent 
fibrinous 
mucositis/ 
may include 
severe pain 
requiring 
narcotic 
Ulceration, 
hemorrhage 
or necrosis 
pharynx & 
esophagus 
No 
change 
over 
baseline 
Mild dysphagia 
or odynophagia/ 
may require 
topical anesthetic 
or non-narcotic 
analgesics/ may 
require soft diet 
Moderate 
dysphagia or 
odynophagia/ 
may require 
narcotic 
analgesics/ 
may require 
puree or liquid 
diet 
Severe 
dysphagia or 
odynophagia 
with 
dehydration 
or weight 
loss(>15% 
from pre-
treatment 
baseline) 
requiring N-
G feeding 
tube, I.V. 
fluids or 
hyper 
alimentation 
Complete 
obstruction, 
ulceration, 
perforation, 
fistula 
SALIVARY 
GLAND 
No 
change 
over 
baseline 
Mild mouth 
dryness/ slightly 
thickened saliva/ 
may have 
slightly altered 
taste such as 
Moderate to 
complete 
dryness/ thick, 
sticky saliva/ 
markedly 
altered taste 
 Acute 
salivary 
gland 
necrosis 
metallic taste/ 
these changes not 
reflected in 
alteration in 
baseline feeding 
behavior, such as 
increased use of 
liquids with 
meals 
 
laryngitis 
No 
change 
over 
baseline 
Mild or 
intermittent 
hoarseness/cough 
not requiring 
antitussive/ 
erythema of 
mucosa 
Persistent 
hoarseness but 
able to 
vocalize/ 
referred ear 
pain, sore 
throat, patchy 
fibrinous 
exudate or 
mild arytenoid 
edema not 
requiring 
narcotic/  
antitussive 
Whispered 
speech, throat 
pain or 
referred ear 
pain 
requiring 
narcotic/ 
confluent 
fibrinous 
exudate, 
marked 
arytenoid 
edema 
Marked 
dyspnea, 
stridor or 
hemoptysis 
with 
tracheostomy 
or intubation 
necessary 
 
HEMATOLOGICAL TOXICITY 
Grade  0 1 2 3 4 
HEMATOLOGIC WBC 
(X 1000) 
>=4.0 3.0 - 
<4.0 
2.0 - 
<3.0 
1.0 - 
<2.0 
<1.0 
PLATELETS (X 1000) >=100 75 - 
<100 
50 - 
<75 
25 - 
<50 
<25 or spontaneous 
bleeding 
NEUTROPHILS >=1.9 1.5 - 
<1.9 
1.0 - 
<1.5 
0.5 - 
<1.0 
<0.5 or sepsis 
HEMOGLOBIN (GM %) >11 11-9.5 <9.5 - 
7.5 
<7.5 - 
5.0 
- 
 GUIDELINES: The criteria are relevant from day 1, the commencement of 
therapy, through day 90. All toxicities Grade 3, 4 or 5
*
 must be verified by 
the Principal Investigator. Any toxicity which caused death is graded 5. 
  
ANNEXURE II 
COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS 
CTCAE VERSION 4. 
GRADE 1 2 3 4 5 
NAUSEA Loss of 
appetite 
without 
alteration 
in eating 
habits 
Oral intake 
decreased 
without 
significant 
weight loss, 
dehydration 
or 
malnutrition. 
Inadequate 
oral caloric or 
fluid intake, 
tube feeding, 
TPN, or 
hospitalization 
indicated. 
- - 
 
Grade  1 2 3 4 5 
vomitin
g 
1-2 
episodes  
(separate
d by 5 
minutes) 
in 24 hrs 
3-5 
episodes 
(separate
d by 5 
minutes) 
in 24 hrs 
>/=6 episodes 
(separated by 
5 minutes) in 
24 hrs,tube 
feeding,TPN 
or 
hospitalizatio
n indicated 
Life-threatening 
consequences,urge
nt intervention 
indicated 
deat
h 
 
 
 
  
INFORMATION TO PARTICIPANTS 
 
TITLE: ROLE OF HYPERFRACTIONATED RADIOTHERAPY 
WITH WEEKLY DOCETAXEL IN LOCALLY ADVANCED 
UNRESECTABLE HEAD AND NECK CANCER 
 
Principal investigator: Dr.JEYASANKAR.S 
 
Name of the participant: 
 
Site: Department of Radiotherapy, Madras Medical College & RGGGH, 
Chennai-3. 
 
You are invited to take part in the research/study/procedure. The information 
in this document is meant to help you decide whether or not to take 
part.Please feel free to ask if any queries. 
What is the purpose of the study?The incidence of head and neck cancer 
has been increasing worldwide .Local recurrences is a major problem after 
intensive curative treatment. With our treatment methodology we are aiming 
to give a better quality of life for the patient by achieving a better immediate 
locoregional response and less treatment related toxicity. 
We have obtained permission from the Institutional Ethics Committee. 
 
The study design: Single arm prospective study. 
Study procedures: Patients will need to undergo blood investigations, CT 
scan neck, Xray chest, dental prophylaxis and smoking cessation 
counselling, if smoker which were done routinely in all head and neck 
cancer patients. These tests are essential to assess the status of the disease. 
The purpose of this study is to find the use of weekly Docetaxel concurrently 
with radiotherapy is feasible in LAHNC and whether it will have a better 
response rate. 
 
Possible risks to you: None greater than patients receiving standard 
radiotherapy.  
 
Possible benefits to you: Better response at the tumour less toxicity from 
treatment. 
 
Possible benefits to other people: The results of the research mat provide 
benefits to the society in terms of advancement of medical knowledge and/or 
therapeutic benefits to future patients. 
 
Confidentiality of the information obtained from you: You have the right 
to confidentiality regarding the privacy of your medical 
information[personal details, physical examination, investigations and your 
medical history]. B y signing this document you will be allowing the 
research team investigators, other study personal, Institutional ethics 
committee and any person or agency required by law like the drug controller 
general of India to view your data, if required.The information from this 
study, if published in scientific journals or presented at scientific meetings, 
will not reveal your identity. 
 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your 
medical care or your relationship with the investigator or the institution.You 
will be taken care of and you will not lose any benefits to which you are 
entitled. 
 
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right 
to withdraw from this study at time during the course of the study without 
giving any reasons. You will still continue to receive the standard treatment 
if you decide so. However, it is advisable that you talk to the research team 
prior to stopping the treatment/discontinuing of procedures etc.  
 
 
 
 
Signature of investigator       Signature of the      
participant 
                                   INFORMED CONSENT FORM 
TITLE: ROLE OF HYPERFRACTIONATED RADIOTHERAPY 
WITH WEEKLY DOCETAXEL IN LOCALLY ADVANCED 
UNRESECTABLE HEAD AND NECK CANCER 
 
NAME OF THE PARTICIPANT: 
NAME OF THE PRINCIPAL INVESTIGATOR: DR.S.JEYASANKAR, 
NAME OF THE INSTITUTION: MADRAS MEDICAL COLLEGE 
 
I_____________________________ have read the information in this form 
(or it has been read to me). I was free to ask any questions and they have 
been answered. I am over 18 years of age and, exercising myfree power of 
choice, hereby give my consent to be included as a participant in this study. 
 
1. I have read and understood this consent form and the information 
provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study. 
4. I have been explained about my rights and responsibilities by the 
investigator. 
5. I have been informed the investigator of all the treatments I am taking or 
have taken in the past 12 months including any native (alternative) 
treatment. 
6. I have been advised about the risks associated with my participation in 
this study.* 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer 
unusual symptoms. * 
8. I have not participated in any research study within the past 12month(s). * 
9. I agree to undergo complete blood count, renal and liver function test, 
chest x ray, CT scan   of the head and  neck 
10. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital. * 
11. I am also aware that the investigator may terminate my participation in 
the study at any time, for any reason, without my consent. * 
12. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented. 
13. I have understand that my identity will be kept confidential if my data 
are publicly presented 
14. I have had my questions answered to my satisfaction. 
15. I have decided to be in the research study. 
 
I am aware that if I have any question during this study, I should contact the 
investigator. By signing this consent form I attest that the information given 
in this document has been clearly explained to me and understood by me, I 
will be given a copy of this consent document 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
Name ________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name ________________ Signature_________________ 
Date________________ 
Address and contact number of the impartial witness: 
 
Name and Signature of the investigator or his representative obtaining 
consent 
Name ________________ Signature_________________ Date__________ 
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